Ley B, et al. – This work was performed to assess the barriers to routine G6PD testing prior to treatment with primaquine. Authors identified three barriers to the roll–out of routine G6PD testing: (a) a perceived low risk of drug–induced haemolysis; (b) the perception that vivax malaria was benign and accordingly treatment with primaquine was not regarded as a priority; and, (c) the additional costs of introducing routine testing. Findings thereby suggested the necessity for greater efforts to increase awareness of the benefits of the radical cure of Plasmodium vivax. They recommend supporting this by economic analyses exploring the cost effectiveness of routine G6PD testing.